Is tofacitinib a game-changing drug for ulcerative colitis?

Autores da FMUP
Participantes de fora da FMUP
- Estevinho, MM
Unidades de investigação
Abstract
The increasing knowledge on ulcerative colitis' pathophysiology has contributed to the expansion of the therapeutic arsenal for this condition. However, to date, 25-40% of patients with ulcerative colitis remain primary or secondary non-responders to therapy, and up to 10% need to eventually undergo a colectomy. Janus kinase inhibitors block cytokine signalling involved in the pathogenesis of several inflammatory conditions. Tofacitinib is the first drug of this class approved for moderate-to-severely active ulcerative colitis in patients for whom disease worsened and those who did not improve with conventional therapy (aminosalicylates, corticosteroids and immunosuppressants) or monoclonal antibodies. We aimed to review the main aspects and concerns related to the current use of tofacitinib and to explore its future application.
Dados da publicação
- ISSN/ISSNe:
- 2050-6406, 2050-6414
- Tipo:
- Review
- Páginas:
- 755-763
- Link para outro recurso:
- www.scopus.com
United European Gastroenterology Journal John Wiley & Sons Inc.
Citações Recebidas na Web of Science: 11
Citações Recebidas na Scopus: 13
Documentos
- Não há documentos
Filiações
Keywords
- Case report; inflammatory bowel disease; Janus kinase inhibitors; tofacitinib; ulcerative colitis
Proyectos asociados
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Magro F,Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis?. United Eur. Gastroenterol. J. 2020. 8(7):p. 755-763. IF:4,623. (2).